INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
77.71
+1.34 (+1.75%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close76.37
Open76.30
Bid71.00 x 800
Ask77.76 x 1000
Day's Range75.46 - 77.79
52 Week Range57.00 - 88.83
Volume1,179,398
Avg. Volume1,291,928
Market Cap16.664B
Beta (3Y Monthly)1.01
PE Ratio (TTM)66.88
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire21 hours ago

    Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

    Incyte (INCY) today announces 24-week results from its randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients (18 to 75 years of age) with vitiligo. The study met its primary endpoint, demonstrating that significantly more patients treated with ruxolitinib cream for 24 weeks achieved a ≥50 percent improvement from baseline in the facial vitiligo area severity index (F-VASI50) score compared to patients treated with a vehicle control (non-medicated cream).

  • Business Wire12 days ago

    Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as a First-Line Therapy for Cholangiocarcinoma

    Incyte (INCY) today announced that the first patient has been treated in FIGHT-302, an open-label Phase 3 study evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, compared to gemcitabine with cisplatin chemotherapy, the current standard of care, as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) and activating FGFR2 rearrangements. “We are pleased to initiate FIGHT-302 – the first Phase 3 study of pemigatinib – which we hope will add to the growing body of evidence demonstrating its potential as a safe and effective treatment for patients with cholangiocarcinoma with known FGFR2 rearrangements, a rare and potentially life-threatening form of cancer,” said Steven Stein, M.D., Chief Medical Officer, Incyte.

  • Business Wire13 days ago

    New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib

    WILMINGTON, Del.-- -- Primary efficacy analysis demonstrated promising efficacy for capmatinib irrespective of the prior line of therapy in 97 patients: overall response rate was 68 percent and 41 percent and median duration of response was 11.14 months and 9.72 months, respectively, across treatment-naive and previously-treated patients with locally advanced or metastatic non-small cell lung cancer ...

  • GlobeNewswire19 days ago

    BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings were published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings, a supplement to the Journal of Clinical Oncology. ASCO’s Annual Meeting, taking place May 31-June 4, 2019 at the McCormick Place Convention Center in Chicago, IL, represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology.

  • Business Wire23 days ago

    FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease

    Incyte Corporation (INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi® (ruxolitinib) for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older. Jakafi is the first and only FDA-approved treatment for this indication.

  • Business Wire24 days ago

    Incyte to Present at Upcoming Investor Conference

    Incyte Corporation announced today that it will present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019 at 2:00 pm / 5:00 pm in Rancho Palos Verdes.

  • Business Wire27 days ago

    Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology

    Incyte Corporation (INCY) announces that data from key studies within its inflammation and autoimmunity portfolio will be presented at the 24th World Congress of Dermatology (WCD). Presentations will feature 24-week data from a Phase 2 study of ruxolitinib cream in adult patients with vitiligo, which will be highlighted during the late-breaking research session, and 12-week data from a Phase 2 study of ruxolitinib cream in adult patients with atopic dermatitis.

  • Business Wirelast month

    Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA

    Incyte Corporation announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology Annual Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and the 24th Congress of the European Hematology Association , to be held June 13-16, 2019, in Amsterdam, the Netherlands.

  • GlobeNewswirelast month

    BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all matters addressed at the annual and special meeting (the "Meeting") of the holders of common shares of BriaCell held on April 24, 2019.

  • GlobeNewswirelast month

    Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the first patient has been treated in its Phase 1 trial evaluating safety, tolerability, and preliminary efficacy of MCLA-145 for the treatment of patients with advanced solid tumors. “We are very pleased to announce the initiation of our Phase 1 trial for MCLA-145,” said Andres Sirulnik, M.D., Ph. D., Executive Vice President and Chief Medical Officer of Merus.

  • Business Wirelast month

    Incyte to Present at Upcoming Investor Conferences

    Incyte Corporation announced today that it will present at the following investor conferences during the month of May:

  • Business Wire2 months ago

    Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs

    WILMINGTON, Del.-- -- Total revenues of $498 million and total product-related revenues of $458 million for the quarter ended March 31, 2019 Jakafi ® revenues of $376 million in Q1   2019 , reaffirming full year 2019 revenue guidance range of $1.58-1.65 billion Primary endpoint met in Phase 2 trial of ruxolitinib cream for the treatment of vitiligo; preparations now underway for Phase 3 development ...

  • Business Wire2 months ago

    Incyte to Report First Quarter Financial Results

    Incyte Corporation announced today that it has scheduled its first quarter 2019 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2019.

  • GlobeNewswire2 months ago

    BriaCell Announces Clinical Trial Collaboration Agreement with Incyte

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced a clinical trial collaboration and supply agreement (the “Agreement”) with Incyte  (INCY), a global biopharmaceutical company focused on discovering and developing novel therapeutics in oncology and other serious diseases. The Agreement is focused on, but not limited to, the selection of novel combinations for the treatment of advanced breast cancer along with a planned clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s selected compounds for advanced breast cancer.

  • GlobeNewswire2 months ago

    Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019

    Merus N.V. (MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, and in collaboration with Incyte (INCY), presented preclinical data from the MCLA-145 program at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA. Merus and Incyte presented two posters outlining preclinical data on MCLA-145, the Biclonics® program targeting CD137 and PD-L1, on Sunday, March 31.

  • GlobeNewswire4 months ago

    New Research Coverage Highlights Nasdaq, Constellation Brands, Incyte, IMAX, HNI, and Frank's International N.V — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire4 months ago

    Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019

    The MPN community is encouraged to participate in awareness initiatives and access new resources at VoicesofMPN.com. Incyte Corporation (INCY) announced today that it has again joined with the National Organization for Rare Disorders (NORD), the European Organizations for Rare Diseases and other health organizations and advocates in recognizing Rare Disease Day 2019 – an initiative that raises awareness of rare diseases and the impact they can have on the lives of patients and caregivers. In honor of the day, Incyte is supporting several efforts intended to educate and increase awareness of myeloproliferative neoplasms (MPNs), a group of rare, chronic blood cancers.

  • Business Wire4 months ago

    Data from Incyte’s Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019

    Incyte Corporation announces that seven abstracts showcasing data from its cancer research portfolio will be presented at the upcoming American Association for Cancer Research Annual Meeting 2019.

  • Business Wire4 months ago

    Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs

    WILMINGTON, Del.-- -- Total product-related revenues of $468 million in 4Q 2018 and $1.7 billion for the full year 2018 Jakafi ® revenues of $380 million in 4Q   2018 and $1.4 billion for the full year 2018 Multiple late-stage product candidates provide additional opportunities to further accelerate revenue growth Conference Call and Webcast Scheduled Today at 8:00 a.m. EST Incyte Corporation today ...

  • Business Wire4 months ago

    Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease

    Incyte (INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi®) for the treatment of patients with acute graft-versus-host disease (GVHD) who have had an inadequate response to corticosteroids. The FDA extended the action date to allow time to review additional data submitted by Incyte in response to the FDA’s information requests. The submission of the additional information has been determined by the FDA to constitute a Major Amendment to the sNDA, resulting in an extension of the PDUFA goal date by three months.

  • Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
    PR Newswire4 months ago

    Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

    INDIANAPOLIS, Feb. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis (AD). In both investigational trials, compared to patients treated with placebo, a statistically significant proportion of patients treated with baricitinib achieved the primary endpoint at Week 16 defined by the Investigator's Global Assessment for AD (IGA) score of clear or almost clear (IGA 0,1). In the 16-week placebo-controlled phase of BREEZE-AD1 and BREEZE-AD2, the incidence of treatment-emergent adverse events and serious adverse events with baricitinib treatment was similar to placebo, and the most common treatment-emergent adverse events observed were nasopharyngitis and headache.

  • GlobeNewswire5 months ago

    Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics — Future Expectations, Projections Moving into 2019

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Incyte and Repligen

    NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...

  • Business Wire5 months ago

    Incyte to Report Fourth Quarter and Year-end Financial Results

    Incyte Corporation announced today that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcast for 8:00 a.m. ET on Thursday, February 14, 2019.